Correlation of Circulating Endoglin with Clinical Outcome in Biliary Atresia

Abstract

Background and Aim: Biliary atresia (BA) is a chronic progressive inflammatory disorder of the extrahepatic and intrahepatic biliary system in children. The aim of the present study was to investigate circulating endoglin levels in BA patients compared with healthy controls and to determine the relationship between plasma endoglin levels and outcome parameters of BA patients after Kasai operation.

Methods: Fifty-five postoperative BA patients and 14 healthy controls were recruited. The patients were divided into two groups based on their serum total bilirubin levels (TB<34.2, no jaundice vs. TB≥34.2 μmol/L, persistent jaundice) and serum alanine aminotransferase (ALT<45, normal ALT vs. ALT≥45 IU/L, high ALT). Circulating endoglin levels were analyzed by enzyme-linked immunosorbent assay.

Results: Average levels of plasma endoglin were significantly higher in BA patients compared to healthy controls (7.8±0.4 vs. 6.5±0.4 ng/mL; p=0.02). BA patients with persistent jaundice had higher plasma endoglin levels than those without jaundice (9.2±0.8 vs. 6.9±0.3 ng/mL; p=0.006). Furthermore, the concentrations of plasma endoglin in BA patients with high ALT were significantly higher compared to those with normal ALT (8.5±0.5 vs. 6.3±0.5 ng/mL, p=0.003). In addition, BA patients with portal hypertension had more elevated plasma endoglin levels than those without portal hypertension (8.8±0.6 vs. 6.1±0.3 ng/mL, p=0.001). Plasma endoglin was positively correlated with serum ALT (r=0.36, p=0.007) and serum GGT (r=0.44, p=0.001).

Conclusion: High circulating endoglin correlated with a poor outcome for BA. Plasma endoglin can be utilized as a potential biomarker reflecting the severity of ongoing liver injury and biliary obstruction in BA patients after Kasai procedure.

Key words

biliary atresia - clinical outcome - endoglin - jaundice

References

• 1 A-Kader HH, Abdel-Hameed A, Al-Shabrawi M. et al . Is biliary atresia an autoimmune disease?.  Eur J Gastroenterol Hepatol. 2003;  15 447
• 2 Asanza CG, García-Monzón C, Clemente G. et al . Immunohistochemical evidence of immunopathogenetic mechanisms in chronic hepatitis C recurrence after liver transplantation.  Hepatology. 1997;  26 755-763
• 3 Barbara NP, Wrana JL, Letarte M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily.  J Biol Chem. 1999;  274 584-594
• 4 Bissell DM, Roulot D, George J. Transforming growth factor β and the liver.  Hepatology. 2001;  34 859-867
• 5 Cheifetz S, Bellón T, Calés C. et al . Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells.  J Biol Chem. 1992;  267 19027-19030
• 6 Clemente M, Núñez O, Lorente R. et al . Increased intrahepatic and circulating levels of endoglin, a TGF-beta1 co-receptor, in patients with chronic hepatitis C virus infection: relationship to histological and serum markers of hepatic fibrosis.  J Viral Hepat. 2006;  13 625-632
• 7 Davenport M. Biliary atresia.  Semin Pediatr Surg. 2005;  14 42-48
• 8 Dharmapatni AA, Smith MD, Ahern MJ. et al . The TGF beta receptor endoglin in systemic sclerosis.  Asian Pac J Allergy Immunol. 2001;  19 275-282
• 9 Diez-Marques L, Ortega-Velazquez R, Langa C. et al . Expression of endoglin in human mesangial cells: modulation of extracellular matrix synthesis.  Biochim Biophys Acta. 2002;  1587 36-44
• 10 Díaz-Gil JJ, García-Monzón C, Rúa C. et al . The anti-fibrotic effect of liver growth factor is associated with decreased intrahepatic levels of matrix metalloproteinases 2 and 9 and transforming growth factor beta 1 in bile duct-ligated rats.  Histol Histopathol. 2008;  23 583-591
• 11 García-Monzón C, Martín-Pérez E, Iacono OL. et al . Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity.  J Hepatol. 2000;  33 716-724
• 12 García-Monzón C, Sánchez-Madrid F, García-Buey L. et al . Vascular adhesion molecule expression in viral chronic hepatitis: evidence of neoangiogenesis in portal tracts.  Gastroenterology. 1995;  108 231-241
• 13 Graulich W, Nettelbeck DM, Fischer D. et al . Cell type specificity of the human endoglin promoter.  Gene. 1999;  227 55-62
• 14 Gressner AM, Weiskirchen R, Breitkopf K. et al . Roles of TGF-beta in Hepatic fibrosis.  Front Biosci. 2002;  7 D793-D807
• 15 Honsawek S, Chongsrisawat V, Vejchapipat P. et al . Serum interleukin-8 in children with biliary atresia: relationship with disease stage and biochemical parameters.  Pediatr Surg Int. 2005;  21 73-77
• 16 Honsawek S, Chongsrisawat V, Vejchapipat P. et al . Association of serum levels of tissue inhibitors of metalloproteinase-1 with clinical outcome in children with biliary atresia.  Asian Pac J Allergy Immunol. 2006;  24 161-166
• 17 Honsawek S, Chongsrisawat V, Vejchapipat P. et al . Elevation of serum stem-cell factor in postoperative biliary atresia.  Pediatr Int. 2007;  49 888-893
• 18 Honsawek S, Chongsrisawat V, Vejchapipat P. et al . High levels of serum basic fibroblast growth factor in children with biliary atresia.  Hepatogastroenterology. 2008;  55 1184-1188
• 19 Karrer FM, Price MR, Bensard DD. Long-term results with the Kasai operation for biliary atresia.  Arch Surg. 1996;  131 493-496
• 20 Kobayashi H, Stringer MD. Biliary atresia.  Semin Neonatol. 2003;  8 383-391
• 21 Letamendía A, Lastres P, Botella LM. et al . Role of endoglin in cellular responses to transforming growth factor-β: A comparative study with betaglycan.  J Biol Chem. 1998;  273 33011-33019
• 22 Massagué J, Attisano SL, Wrana SL. The TGF-β family and its composite receptors.  Trends Cell Biol. 1994;  4 172-178
• 23 Vejchapipat P, Theamboonlers A, Chaokhonchai R. et al . Serum hepatocyte growth factor and clinical outcome in biliary atresia.  J Pediatr Surg. 2004;  39 1045-1049
• 24 Vejchapipat P, Theamboonlers A, Poomsawat S. et al . Serum transforming growth factor-beta 1 and epidermal growth factor in biliary atresia.  Eur J Pediatr Surg. 2008;  18 415-418
• 25 Westphal JR, Willems HW, Schalkwijk CJ. et al . A new 180-kDa dermal endothelial cell activation antigen: in vitro and in situ characteristics.  J Invest Dermatol. 1993;  100 27-34
• 26 Yagmur E, Rizk M, Stanzel S. et al . Elevation of endoglin (CD105) concentrations in serum of patients with liver cirrhosis and carcinoma.  Eur J Gastroenterol Hepatol. 2007;  19 755-761
• 27 Yu D, Zhuang L, Sun X. et al . Particular distribution and expression pattern of endoglin (CD105) in the liver of patients with hepatocellular carcinoma.  BMC Cancer. 2007;  7 122

Correspondence